Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 106 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Leucine Clear all
Not listed Not applicable Interventional

Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion

NCT00005889
View directory record Official record
Conditions
Infant, Low Birth Weight, Hyperglycemia
Interventions
alanine, amino acids, glucagon, glucose, glutamine, glycerol, insulin, leucine, lipids, urea
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
4 Days to 6 Days
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

NCT03976349
View directory record Official record
Conditions
Parkinson's Disease
Interventions
BIIB094, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Farmington Hills, Michigan • Cleveland, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Hydroxyproline Influence on Oxalate Metabolism

NCT02038543
View directory record Official record
Conditions
Hyperoxaluria
Interventions
Hydroxyproline and Leucine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
15 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Not applicable Interventional

Resveratrol-Leucine Metabolite Synergy in Pre-diabetes

NCT01593605
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Resveratrol, resveratrol /HMB, Placebo treatment
Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 17, 2026, 2:49 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

NCT04875975
View directory record Official record
Conditions
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Interventions
Rozanolixizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Aurora, Colorado • Jacksonville, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Intake and Circulating Levels of Branched Chain Amino Acids

NCT02110602
View directory record Official record
Conditions
Dietary Intake of Branched Chain Amino Acids
Interventions
Diet high in amino acid levels, Diet low in amino acid levels
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 40 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Not applicable Interventional

Effects of Nutritional Supplementation (Product 4808) on Acute Skeletal Muscle Protein Synthesis in Cancer Patients

NCT00446888
View directory record Official record
Conditions
Cancer
Interventions
Standardized Meals for Diet Stabilization, Forticare, Product 4808
Behavioral · Dietary Supplement
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2009 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional

N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

NCT01885338
View directory record Official record
Conditions
Schizophrenia
Interventions
N-acetylcysteine (NAC), Inactive placebo capsule
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 17, 2026, 2:49 PM EDT
Completed No phase listed Observational

Human CNS Tau Kinetics in Tauopathies

NCT03545126
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD MAPT Mutation)
Interventions
13C6 Leucine
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

NCT06531811
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD8630 (test formulation) via test inhaler, AZD8630 (reference formulation) via Monodose inhaler, Test inhaler, Monodose inhaler
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 17, 2026, 2:49 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830
View directory record Official record
Conditions
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Interventions
NEU-411, Placebo
Drug · Other
Lead sponsor
Neuron23 Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
45
States / cities
Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Not applicable Interventional Results available

SmART-TBI: Supplementation With Amino Acid Rehabilitative Therapy in TBI

NCT04603443
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Branched Chain Amino Acids, Protein Control
Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 2:49 PM EDT
Completed No phase listed Observational

PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)

NCT01536821
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Weston, Florida • Indianapolis, Indiana • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Regulation of Branched-chain Amino Acid Metabolism in Pre-Diabetes

NCT01786941
View directory record Official record
Conditions
Branched-chain Amino Acid Metabolism, Insulin Sensitivity
Interventions
Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training, GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery
Other
Lead sponsor
Duke University
Other
Eligibility
30 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 17, 2026, 2:49 PM EDT
Terminated Phase 2 Interventional Results available

Rapid Antidepressant Effects of Leucine

NCT03079297
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
L-Leucine, Maltodextrin
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients

NCT02151461
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Metformin, Metformin, Mid Metformin, High Metformin
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Not applicable Interventional

BCAA Supplemental Study

NCT03339232
View directory record Official record
Conditions
Cirrhosis
Interventions
BCAA Supplement, Physical Activity
Dietary Supplement · Other
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 17, 2026, 2:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease

NCT03938870
View directory record Official record
Conditions
Alzheimer's Disease, Brain Diseases, Central Nervous System Diseases, Delirium, Dementia, Amnestic, Cognitive Disorders, Dementia, Mental Disorders, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies
Interventions
L-Leucine 13C6
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 17, 2026, 2:49 PM EDT
Recruiting Not applicable Interventional

Protein Supplementation After ACL Surgery

NCT06311058
View directory record Official record
Conditions
ACL Reconstruction
Interventions
Whey protein isolate, Protein + BAA, Placebo
Dietary Supplement
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
16 Years to 40 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 17, 2026, 2:49 PM EDT
Terminated Not applicable Interventional

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

NCT04784234
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
GlaucoCetin, Placebo
Dietary Supplement · Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 17, 2026, 2:49 PM EDT
Recruiting Phase 2 Interventional

RESvEraTrol in Parkinson's Disease (RESET)

NCT07592767
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Trans-Resveratrol
Drug
Lead sponsor
Georgetown University
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Not applicable Interventional

Hydrolyzed Casein and Whey Protein Supplementation and the Addition of Leucine to Induce Protein Anabolism in Malnourished COPD Patients

NCT01154400
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Casein protein hydrolysates, Whey protein hydrolysates, Casein protein hydrolysates + LEU, Whey protein hydrolysates + LEU
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients

NCT01211717
View directory record Official record
Conditions
Type 2 Diabetes, Healthy Individuals
Interventions
Branched Chained Amino Acids, Cellulose Placebo mix
Dietary Supplement · Other
Lead sponsor
Loma Linda University
Other
Eligibility
20 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2011 · Synced Oct 17, 2026, 2:49 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
D. Walter Wray
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 2:49 PM EDT